Kenvue stock has recently seen its consensus analyst price target decrease modestly from $21.70 to $20.63. This slight adjustment reflects a mix of new insights, as analysts weigh fresh legal and reputational risks against potential value opportunities from strategic changes. Stay tuned to discover how investors and observers can best monitor the evolving narrative around Kenvue in the coming months.
What Wall Street Has Been Saying
The past several weeks have brought a flurry of updates from Wall Street analysts regarding Kenvue, many of which reflect both optimism for the company’s long-term potential and concerns about ongoing legal and reputational headwinds. Below is a summary of the most notable perspectives from major research firms.
? Bullish Takeaways
-
BofA reiterated its Buy rating, stating that Kenvue’s post-selloff valuation has created a “particularly attractive entry point” for investors, with a discounted price relative to household and personal care peers. The firm’s price target is set at $21, recently lowered from $25, reflecting adjusted sector-wide estimates but continued confidence in Kenvue’s execution and the achievability of new guidance.
-
Rothschild & Co Redburn upgraded Kenvue to Buy, emphasizing a now “clear path to value creation” as the company’s strategic review unfolds. The firm highlights the significant trading discount to its sum-of-the-parts valuation (over 40%) and views recent regulatory developments as less severe than initially feared. Their target stands at $22.
-
Despite concerns around Tylenol, Evercore ISI notes that the recent share selloff might be overdone, arguing that the lack of causal scientific evidence for alleged product risks could limit any long‑term impact. The analyst acknowledges the premium commanded by Tylenol within Kenvue’s portfolio and has set a revised price target of $23.
-
Analysts reward Kenvue’s management for recent transparency, cost‑control measures, and strategic responsiveness, especially in light of recent headline risks and reset financial guidance.
? Bearish Takeaways
-
Citi has turned increasingly cautious, reiterating a Neutral rating and reducing its price target from $22 to $17. The analyst cited emerging legal risks outside the U.S. and Canada related to the talc litigation in the UK and lingering uncertainties from earlier U.S. cases against Johnson & Johnson, noting these could weigh on sentiment and lead to near‑term volatility.
-
Barclays lowered its price target to $17 and maintained an Equal Weight rating, flagging “muted and decelerating” growth across key personal‑care categories as a concern for Kenvue’s topline momentum.
-
Evercore ISI reduced its target to $18 (from $23 previously) citing new regulatory scrutiny on Tylenol, a vital driver of Kenvue’s revenues. The firm points to increased headline and reputational risks & the potential for shifts in consumer behavior, though it maintains an In‑Line rating.
-
RBC Capital highlighted that while legal threats to Tylenol have not yet proven causation in court, the risk of continued litigation and media attention could cap near‑term valuation upside.
-
Many firms are closely monitoring both valuation and execution quality, with some cautioning that risks from high‑profile legal issues and regulatory developments may still not be fully reflected in the stock price.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story.
What’s in the News
-
Johnson & Johnson and Kenvue’s subsidiary have filed a lawsuit alleging that the talc litigation in the UK was predicated on fraudulent documentation. This lawsuit claims that the court’s decision against Kenvue to deflect liability has resulted in a breach of fiduciary duties, jeopardizing Kenvue’s reputation.
-
Citi analysts have issued a cautious outlook on Kenvue’s price target, citing a reduction in the projected discount rate and a slight erosion of the company’s long‑term financial prospects due to intensified legal scrutiny and operational uncertainties.
-
The Trump Administration has announced plans to issue consumer safety warnings about Kenvue’s products, citing new evidence that could affect the company’s public image and compliance obligations.
-
Kenvue announced a new strategic partnership with a leading technology firm to accelerate its product development pipeline and enhance regulatory compliance.
How This Changes the Fair Value For Kenvue
-
The consensus analyst price target has decreased modestly.
-
The discount rate has edged up slightly.
-
Revenue growth expectations have dipped marginally.
-
Net profit margin has eased fractionally.
-
The future P/E ratio has declined.
Companies discussed in this article include KVUE.